ASH 2020 Meeting Highlights in Acute Myeloid Leukemia
Please complete Pre-test
Chapter 1 of 2
Release Date: March 26, 2021
Expiration Date: March 26, 2022
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, experts will review select abstracts from the 2020 ASH Annual Meeting and explore how this data can be used to guide treatment selection in AML. Topics will include outcomes of trials combining venetoclax and hypomethylating agents in both the upfront and second-line setting, new data on FLT3 inhibitor/venetoclax combination therapy, triple therapy with hypomethylating agents, venetoclax, and IDH inhibitors, results from the QUAZAR trial evaluating oral azacitidine versus placebo as maintenance therapy, and new data on CPX-351.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Summarize clinical data supporting advances in novel treatment approaches and best practices for use of available treatments
- Demonstrate the ability to evaluate, integrate, and apply appropriate information from various sources of clinical data as it relates to emerging treatments and practice standards in AML
Chapter 1: VIALE-A Study, MRD after Venetoclax and Decitabine, Venetoclax Therapy for Relapsed and Treatment Refractory AML – Ross Levine, MD; Harry P. Erba, MD, PhD; and Eytan M. Stein, MD
Chapter 2: Maintenance Therapy, FLT3 Inhibitor Therapy, Gilteritinib with Chemotherapy – Ross Levine, MD; Harry P. Erba, MD, PhD; and Eytan M. Stein, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 26, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Ross Levine, MD
Professor of Medicine
Weill Cornell Medical College
Chief, Molecular Cancer Medicine Service
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Ross Levine earned his medical degree from Johns Hopkins. He served as a resident in internal medicine at Massachusetts General Hospital and as a hematology-oncology fellow at Dana-Farber Cancer Institute. Dr. Levine is a Professor of Medicine at Weill Cornell Medical College, and Chief of the Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. He is also an Attending Physician on the Leukemia Service, Department of Medicine, and the Laurence Joseph Dineen Chair in Leukemia Research.
Dr. Levine was elected to the American Society of Clinical Investigation and the Association of American Physicians. He serves on the supervisory board of Qiagen, the scientific advisory board of C4 Therapeutics, Isoplexis, Mana Therapeutics, and was on the scientific advisory board of Loxo Oncology. His laboratory focuses on elucidating the genetic basis of myeloid malignancies, and using this knowledge to improve outcomes for patients with these disorders. His primary research interests include the role of JAK-STAT signaling in malignant transformation and in the effects of mutations in epigenetic modifiers in clonal hematopoiesis, myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML). Moreover, as a physician scientist, his laboratory has a specific interest in translating this knowledge back to the clinic and in participating in the preclinical and clinical evaluation of targeted therapies for leukemia patients.
Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Durham, North Carolina
Dr. Harry Erba received his medical degree and doctorate in biophysics from Stanford University. He completed an internship and residency in internal medicine, as a well as a fellowship in hematology/oncology at the Brigham and Women's Hospital, Harvard Medical School. He is currently Professor of Medicine and is a member of the Division of Hematologic Malignancy and Cellular Therapy at Duke University. In addition, Dr. Erba serves as the Director of the Leukemia Program, as well as Medical Director of the Hematologic Malignancies Inpatient Service.
As an active member in the SWOG (formerly, Southwest Oncology Group) Leukemia Committee for over a decade, Dr. Erba worked closely with the leadership of the SWOG Leukemia, Lymphoma, Myeloma and Bone Marrow Transplant Committees. He has served as the Chairman of the SWOG Leukemia Committee, and serves on the NCI Leukemia Steering Committee.
Dr. Erba has focused on the assessment of novel therapies in acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, and other myeloproliferative neoplasms. He has been involved in numerous clinical trials in these hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs.
Eytan M. Stein, MD
Assistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. Dr. Stein is an Assistant Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center.
Dr. Stein conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. He led the clinical studies of the IDH2 inhibitor enasidenib and the IDH1 Inhibitor ivosidenib in patients with relapsed and refractory acute myeloid leukemia (AML) that led to FDA approval in 2017 and 2018. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the Beat AML® Master Clinical Trial. Dr. Stein’s current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery, and Blood. In addition, he serves on the editorial boards of Blood and Leukemia and Lymphoma.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-012-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-012-139
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Ross Levine is on the supervisory board of QIAGEN and Zentalis Pharmaceuticals, and is a scientific advisor to Ajax Therapeutics, Inc., Auron Therapeutics, C4 Therapeutics, Imago BioSciences, Isoplexis, Kurome Therapeutics, Mana Therapeutics, Mission Bio, and Scorpion Therapeutics, which each include an equity interest. He has consulted for Celgene Corporation ‒ A Bristol-Myers Squibb Company; received research support from Constellation Pharmaceuticals and Prelude Therapeutics; and consulted for Bridge Therapeutics, Bristol-Myers Squibb Company, Eli Lilly and Company, Incyte Corporation, Janssen Pharmaceuticals, Inc., Jubilant Pharma Limited, and Novartis AG. Dr. Levine has also received honoraria from Constellation, Eli Lilly, and from Gilead for grant reviews.
Dr. Harry Erba has received consultant fees from AbbVie Inc., Agios, Astellas Pharma US, Inc., Celgene Corporation – A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlycoMimetics, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, and Novartis AG, as well as honoraria related to speakers’ bureau activities from AbbVie, Agios, Celgene Corporation – A Bristol-Myers Squibb Company, Incyte, Jazz, and Novartis. He has received grant support related to research activities from AbbVie, Agios, Amgen Inc., Daiichi Sankyo, FORMA Therapeutics, Inc., Forty Seven Inc., GlycoMimetics, ImmunoGen, Inc., Jazz, MacroGenics, Inc., Novartis, and PTC Therapeutics.
Dr. Eytan Stein has received honoraria related to formal advisory activities from and owns significant holdings in AbbVie Inc., Agios, Inc., Astellas Pharma US, Inc., Auron Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech, Inc., Gilead, Janssen Pharmaceuticals, Inc., Syndax Pharmaceuticals, and Syros Pharmaceuticals, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.